⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182073 | 0.57 | — | — | |
| SCHEMBL1462204 | 0.55 | — | — | |
| SCHEMBL47225 | 0.55 | — | — | |
| SCHEMBL2213796 | 0.55 | — | — | |
| SCHEMBL15568358 | 0.52 | MEN1 (0.33) | — | |
| Bromide SCHEMBL3457532 | 0.52 | — | — | |
| SCHEMBL21111126 | 0.52 | ALDH1A1 (0.36) | — | |
| Calcium SCHEMBL8114 | 0.30 | — | — | |
| Calcium SCHEMBL1028141 | 0.30 | — | — | |
| Ammonia Solution, Strong SCHEMBL17559907 | 0.30 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911503-B2 | Manufacturing of semi-plastic pharmaceutical dosage units | INTERVET INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11858904-B2 | Process for preparing large size isoxazoline particles | INTERVET INC. (JE) | 2024-01-02 | — | — | US | disclosed |
| US-11818932-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-14 | — | — | US | disclosed |
| US-20230320981-A1 | SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS | INTERVET INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230310386-A1 | INJECTABLE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTERVET INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11712416-B2 | Solid oral pharmaceutical compositions for isoxazoline compounds | INTERVET INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230233530-A1 | IMPLANTABLE ISOXAZOLINE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTERVET INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11696491-B2 | Organometallic compound, organic light-emitting device including the same and apparatus including the organometallic compound | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-11696499-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-9770440-B2 | Solid oral pharmaceutical compositions for isoxazoline compounds | INTERVET INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170179402-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170179395-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170179397-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170179204-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170179401-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170179396-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170179416-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| WO-2017044828-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170071914-A1 | Topical Localized Isoxazoline Formulation | INTERVET INC. (US) | 2017-03-16 | — | — | US | disclosed |